文献速递心律失常

阵发性心房颤动肺静脉隔离单独与联合附加消融的临床结局

Pulmonary Vein Isolation Alone Versus Adjunctive Ablation for Paroxysmal Atrial Fibrillation
RSS 订阅 · Journal of Cardiovascular Electrophysiology · 2026-10-06

本研究基于TriNetX研究网络,纳入2020年1月至2024年1月接受导管消融的阵发性房颤(PAF)成人患者,比较单纯肺静脉隔离(PVI)与附加肺静脉外消融(PVI+)的真实世界应用及预后。倾向匹配分析显示,PVI+策略在复发、重复消融、复律、抗心律失常药物使用及进展为持续性房颤方面均劣于单纯PVI。结论支持指南推荐:阵发性房颤首次消融应优先选择单纯PVI。

要点

  • 真实世界中27.2%的首次PAF消融采用PVI+策略
  • PVI+较单纯PVI复发风险增加28%(HR 1.28,95%CI 1.16–1.42)
  • PVI+导致非典型房扑风险增加2.63倍,进展为持续房颤风险增加37%

核心结论

  • 首次阵发性房颤消融术中附加肺静脉外消融(PVI+)在真实世界中仍较常见,但其术后复发、重复消融、复律、抗心律失常药使用、非典型房扑及进展为持续性房颤的结局均劣于单纯肺静脉隔离(PVI),不支持在阵发性房颤中常规添加附加消融

研究设计与样本

  • 使用TriNetX研究网络的数据,纳入2020年1月至2024年1月接受导管消融的成人阵发性房颤患者,进行倾向评分匹配(每侧5020例),采用Kaplan-Meier分析,随访3年

主要发现

  • 匹配前18891例患者中5134例(27.2%)接受了PVI+策略
  • PVI+组复发风险显著升高(HR 1.28,95%CI 1.16–1.42;p < 0.001)
  • PVI+组重复消融(HR 1.99,95%CI 1.60–2.46;p < 0.0001)、复律(HR 1.37,95%CI 1.13–1.66;p = 0.001)和抗心律失常药使用(HR 1.41,95%CI 1.05–1.87;p = 0.020)均更常见
  • PVI+组进展为持续性房颤风险更高(HR 1.37,95%CI 1.23–1.53;p < 0.001)
  • PVI+组非典型房扑风险显著增加(HR 2.63,95%CI 1.97–3.50;p < 0.0001)

关键数值与推荐

  • 复发定义为3个月空白期后的重复消融、复律或抗心律失常药使用
  • 指南建议阵发性房颤单纯行PVI,本研究结果不支持常规进行附加消融

临床怎么用

  • 对于阵发性房颤首次消融,建议仅行肺静脉隔离而非附加消融
  • 需避免在首次手术中常规增加肺静脉外消融,因其与更差的临床结局相关

局限性

  • 未说明采用何种倾向评分匹配方法及残余混杂可能性
  • 未提供空白期后具体复发率数值(仅HR和CI)

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical Outcomes of Pulmonary Vein Isolation Alone Versus Additional Lesion Sets in Paroxysmal Atrial Fibrillation ABSTRACT Background Pulmonary vein isolation (PVI) is the standard ablation strategy for paroxysmal atrial fibrillation (PAF). Despite guideline recommendations favoring PVI alone in PAF, some operators routinely perform extra pulmonary vein ablation (PVI+) during initial procedures. Objective To determine frequency of PVI+ strategy for treatment of PAF in the real world and examine its impact on arrhythmic recurrence and progression compared to PVI alone. Methods Using the TriNetX research network, we identified adults with PAF who underwent catheter ablation between January 2020 and January 2024. Recurrence was defined as repeat ablation, cardioversion, or antiarrhythmic drug (AAD) use beyond a 3-month blanking period. Progression to persistent AF and atypical atrial flutter were also assessed. Kaplan-Meier analysis was performed with 3-year follow-up. Results Before matching, 5134 of 18,891 patients (27.2%) underwent PVI+. In the propensity matched analysis (n = 5020 per group), recurrence was significantly higher in the PVI+ group (HR 1.28, 95% CI 1.16–1.42; p < 0.001). Repeat ablation, cardioversion and AAD use were more common with PVI+ (HR 1.99, 95% CI 1.60–2.46; p < 0.0001, HR 1.37, 95% CI 1.13–1.66; p = 0.001, and HR 1.41, 95% CI 1.05–1.87; p = 0.020, respectively). Progression to persistent AF was higher with PVI+ (HR 1.37, 95% CI 1.23–1.53, p < 0.001), as was atypical atrial flutter (HR 2.63, 95% CI 1.97–3.50; p < 0.0001). Conclusion Extra-pulmonary vein ablation during first-time PAF ablation remains common in real-world practice but is associated with worse outcomes including repeat ablation, cardioversion, AAD use, atrial flutter, and progression to persistent AF.

来源:Journal of Cardiovascular Electrophysiology,查看原文。版权归原作者所有。

引用

  1. Journal of Cardiovascular Electrophysiology:Pulmonary Vein Isolation Alone Versus Adjunctive Ablation for Paroxysmal Atrial Fibrillation

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。